期刊
ACS INFECTIOUS DISEASES
卷 8, 期 6, 页码 1107-1115出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.2c00123
关键词
Chagas disease; drug discovery; evolution model; genetic diversity; life cycle; morphological forms; target product profile; tropism; Trypanosoma cruzi
资金
- Junta de Andalucia [E-BIO-464-UGR20]
- Junta de Andalucia (Proyectos I+D+I FEDER Andalucia 2014-2020)
- Alfonso Martin Escudero Foundation
This Review provides a comprehensive update on our understanding of Chagas disease, including the current life cycle, new morphological forms, and genetic diversity of the parasite, as well as identifying intervention points in the life cycle where new drugs and treatments could achieve a parasitic cure.
Chagas disease (CD) is a parasitic, systemic, chronic, and often fatal illness caused by infection with the protozoan Trypanosoma cruzi. The World Health Organization classifies CD as the most prevalent of povertypromoting neglected tropical diseases, the most important parasitic one, and the third most infectious disease in Latin America. Currently, CD is a global public health issue that affects 6-8 million people. However, the current approved treatments are limited to two nitroheterocyclic drugs developed more than 50 years ago. Many efforts have been made in recent decades to find new therapies, but our limited understanding of the infection process, pathology development, and long-term nature of this disease has made it impossible to develop new drugs, effective treatment, or vaccines. This Review aims to provide a comprehensive update on our understanding of the current life cycle, new morphological forms, and genetic diversity of T. cruzi, as well as identify intervention points in the life cycle where new drugs and treatments could achieve a parasitic cure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据